TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15880021
Drug: Everolimus dose
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus dose reduction
Study: 15880021
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose furosemide
Study: 6144462
Drug: Lorazepam 2.0
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2.0 mg
Study: 20181388
Drug: Different preparation
Normalized name: Indifferent preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different preparation designs (non-retentive, occlusal preparation with chamfer or straight-beveled finishing line)
Study: 19034051
Drug: Genistein (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein (54 mg/d)
Study: 12087568
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa administered IV once weekly
Study: 12087568
Drug: Epoetin administered
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin administered IV three times weekly
Study: 8585775
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg trimethoprim and 800 mg sulfamethoxazole twice a day
Study: 8585775
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ciprofloxacin twice a day
Study: 1974143
Drug: Metoprolol CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR (100 mg)
Study: 1974143
Drug: Beta-adrenoceptor blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoceptor blockers (Propranolol LA, Atenolol, Metoprolol CR)
Study: 875101
Drug: Massive steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massive steroids
Study: 30361080
Drug: Imipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (25 mg once nightly for the first 2 weeks, then 50 mg thereafter)
Study: 20124412
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of prednisolone (single dose)
Study: 20124412
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of prednisolone daily for 15 days
Study: 23676577
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg once daily
Study: 10080158
Drug: IFN‐alpha (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha (6 million units once a day for one month and thrice weekly for five months)
Study: 10080158
Drug: IFN‐beta (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐beta (6 million units once a day daily for two months)
Study: 10080158
Drug: IFN‐beta (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐beta (3 million units twice a day for two months)
Study: 22527350
Drug: Atropine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1.0 mg)
Study: 1970284
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid enemas (4 gm daily for the first seven days of each month)
Study: 1970284
Drug: Oral sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfasalazine (2 gm daily as oral tablets)
Study: 6164465
Drug: Postoperative irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative irradiation (45 Gy) + Bleomycin (15 mg doses, total 180 mg)
Study: 6164465
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care (no radiotherapy or chemotherapy)
Study: 25897676
Drug: selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selumetinib 75 mg p.o. bid
Study: 25897676
Drug: selumetinib 50
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selumetinib 50 mg p.o. bid plus temsirolimus 20 mg i.v. weekly
Study: 21078303
Drug: Perimenopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perimenopausal hormone therapy (HT)
Study: 21078303
Drug: Never users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Never users of hormone therapy (HT)
Study: 17278974
Drug: Alagebrium (ALT-711;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alagebrium (ALT-711; 210 mg twice a day for 8 weeks)
Study: 15126734
Drug: Amoxicillin/Clavulanate (A/C)
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/Clavulanate (A/C)
Study: 15126734
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Clarithromycin and A/C)
Study: 10570555
Drug: Topical terbinafine
Normalized name: terbinafine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical terbinafine 1% cream twice daily for 1 week, followed by placebo cream for 5 weeks
Study: 10570555
Drug: Topical clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clotrimazole 1% cream twice daily for 4 weeks
Study: 320670
Drug: Topical clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clotrimazole
Study: 6981176
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) therapy for treatment: 20 mg of TMP and 100 mg of SMZ per kg of body weight per day
Study: 6981176
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) prophylactic therapy: 5.0 mg of TMP and 25 mg of SMZ per kg of body weight per day
Study: 30507267
Drug: 12% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% carbohydrate plus electrolyte (CHO‐E) solution
Study: 24296423
Drug: L. reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. reuteri combination (2×10 Colony Forming Units)
Study: 24296423
Drug: L. reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. reuteri combination
Study: 22676424
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg orally for 6 days)
Study: 10627793
Drug: Paroxetine (20-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20-50 mg/day flexible dose)
Study: 6367380
Drug: Parenteral antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antihypertensive therapy
Study: 22115710
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of sirolimus (220, 440, 880, 1320, or 1760 μg)
Study: 22115710
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of sirolimus (44, 110, 176, 264, or 352 μg)
Study: 21969992
Drug: Initial estimate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial estimate of the unknown factors of the G-computation formula
Study: 15037403
Drug: GnRH‐a administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a administration starting on stimulation day 6 (group 1)
Study: 15037403
Drug: GnRH‐a administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a administration starting when the leading follicle reached a mean diameter of 14 mm (group 2)
Study: 11860914
Drug: Calcium lactate
Normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium lactate tablets (800 mg of calcium daily)
Study: 1432027
Drug: Sequential strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential strategy for determining antihypertensive intervention
Study: 6499663
Drug: Oral instructions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral instructions alone or in combination with written information
Study: 6499663
Drug: Medication reminder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reminder calendar
Study: 6499663
Drug: Medication reminder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reminder package
Study: 6499663
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of reminder aid with oral reinforcement
Study: 12529740
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus oral anticoagulants (group B)
Study: 1090418
Drug: Indapamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (5 mg daily)
Study: 1090418
Drug: Chlorothiazide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorothiazide (500 mg daily)
Study: 25698298
Drug: WELLFOCUS PPT
Normalized name: PPT
DrugBank: Podofilox (DB01179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WELLFOCUS PPT + Treatment as Usual (TAU)
Study: 24238308
Drug: Mesna injection
Normalized name: Mesna Injection
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesna injection
Study: 22852055
Drug: Natural orange
Normalized name: Dex4 Natural Orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural orange juice enriched with 11.25 g of levan
Study: 14736583
Drug: e-diaries administered
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-diaries administered via home visits (n=30)
Study: 10577813
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with ventilation tubes
Study: 8597505
Drug: Chemotherapy (5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (5-Fluorouracil and cisplatin)
Study: 1936647
Drug: Occlusin restorations
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusin restorations in butt-joint preparations
Study: 1936647
Drug: Occlusin restorations
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusin restorations in bevel-edged preparations
Study: 27500896
Drug: Serial glycolic
Normalized name: glycolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial glycolic acid (GA) peel every 3 weeks with twice daily 20% azelaic acid (AA) cream
Study: 27500896
Drug: 20% azelaic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% azelaic acid (AA) cream
Study: 26763917
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg triflusal twice a day
Study: 26763917
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel once daily
Study: 24240777
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment aimed at lowering systolic blood pressure by 10% to 25% within the first 24 hours, achieving blood pressure less than 140/90 mm Hg within 7 days, and maintaining this level during hospitalization.
Study: 24240777
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (discontinued all antihypertensive medications during hospitalization).
Study: 24240777
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment group.
Study: 18562427
Drug: alprazolam 1
Normalized name: alprazolam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: alprazolam 1 mg
Study: 18562427
Drug: zolpidem 5
Normalized name: zolpidem 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: zolpidem 5 mg
Study: 17552957
Drug: Tolterodine extended-release
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine extended-release (ER)
Study: 8424580
Drug: Intermittent suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent suction and pressure treatment
Study: 3315536
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg once a day
Study: 31751317
Drug: FMT capsules
Normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMT capsules from a donor enriched in Lachnospiraceae and Ruminococcaceae
Study: 27473187
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (600 IU daily or 3750 IU daily)
Study: 24576844
Drug: Fish oil-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil-based parenteral lipid preparation (FOLP) at 1.5 g/kg/day
Study: 24576844
Drug: Soy-based parenteral
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-based parenteral lipid preparation (SLP) at 1.5 g/kg/day
Study: 24576844
Drug: Fish oil-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil-based parenteral lipid preparation (FOLP)
Study: 15102335
Drug: Clonazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (1 mg)
Study: 9568728
Drug: Sucralfate (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (250 mg)
Study: 8142151
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) alone (arm I: 26 patients)
Study: 3060424
Drug: Clotrimazole 500
Normalized name: clotrimazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 500 mg vaginal tablet once a month
Study: 3060424
Drug: Clotrimazole 500
Normalized name: clotrimazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 500 mg vaginal tablet once a month (after relapse)
Study: 3060424
Drug: Clotrimazole 500
Normalized name: clotrimazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 500 mg vaginal tablet twice a month
Study: 1360087
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of Exosurf (synthetic surfactant)
Study: 1360087
Drug: Delayed selective
Normalized name: omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed selective administration of Exosurf (synthetic surfactant)
Study: 1360087
Drug: Up-to-four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up-to-four doses of surfactant (if signs of RDS persisted or recurred)
Study: 1360087
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of surfactant 12 hours apart
Study: 692138
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment (chemotherapy, radiotherapy, immunotherapy)
Study: 19220164
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of azelastine nasal spray
Study: 19220164
Drug: Original formulation
Normalized name: Zegerid (Original Formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original formulation of azelastine nasal spray
Study: 25370394
Drug: Topical Anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Anesthesia (TA)
Study: 29444530
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no morphine)
Study: 9152099
Drug: Continuous low
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous low dose (2.5‐10 mg every 2 weeks)
Study: 9152099
Drug: Continuous moderate
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous moderate dose (standard) (12.5‐50 mg every 2 weeks)
Study: 8424849
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg SDZ ENA 713
Study: 8424849
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg SDZ ENA 713
Study: 8424849
Drug: 1.3 mg
Normalized name: menthol 1.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 mg SDZ ENA 713
Study: 8424849
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg SDZ ENA 713
Study: 3306291
Drug: Org OD
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org OD 14 (2.5 mg/day, per os)
Study: 27339124
Drug: Morphine spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine spinal anesthesia
Study: 25821098
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of proton pump inhibitor (PPI)
Study: 25821098
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of proton pump inhibitor (PPI)
Study: 23307404
Drug: CHO-PRO (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-PRO (0.8 g sucrose · kg‐1 · hr‐1 with 0.3 g · kg‐1 · hr‐1 whey-protein isolate)
Study: 23307404
Drug: CHO (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (0.8 g sucrose · kg‐1 · hr‐1)
Study: 23307404
Drug: CHO-CHO (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-CHO (1.1 g sucrose · kg‐1 · hr‐1)
Study: 20805294
Drug: Bosentan 62.5
Normalized name: bosentan 62.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 62.5 mg twice daily for 4 weeks and 125 mg twice daily thereafter for 20 weeks (n=98)
Study: 18077611
Drug: Refrigerated formulation
Normalized name: Refrigerant 114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refrigerated formulation of Zostavax (n = 182)
Study: 18077611
Drug: Frozen formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frozen formulation of Zostavax (n = 185)
Study: 3839446
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg aspirin
Study: 2249379
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg codeine
Study: 6108299
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of oxazepam
Study: 6108299
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of temazepam
Study: 26996542
Drug: Control (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (insulin pump therapy)
Study: 24614112
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (500 mg, three times a day)
Study: 24614112
Drug: Cellulose (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose (placebo, 500 mg, three times a day)
Study: 17903568
Drug: Hydrocodone with
Normalized name: Rolatuss with Hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone with acetaminophen
Study: 2147833
Drug: Enoximone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (1 mg/kg by rapid intravenous injection every 8 hours for 48 hours)
Study: 2147833
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (furosemide, nitrates, dopamine‐dobutamine)
Study: 6994771
Drug: Guanfacine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine 2.0 mg
Study: 6994771
Drug: Guanfacine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine 1.0 mg
Study: 6994771
Drug: Clonidine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.15 mg
Study: 6994771
Drug: Clonidine 0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.30 mg
Study: 6994771
Drug: Clonidine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.15 mg and 0.30 mg
Study: 31764741
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen 1 g
Study: 17244178
Drug: Intensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive group cognitive treatment (IGCT)
Study: 22801833
Drug: Nonsurgical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical management (nasolacrimal duct massage and topical antibiotics as needed) for 6 months
Study: 22801833
Drug: Nonsurgical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical management (nasolacrimal duct massage and topical antibiotics as needed)
Study: 17550443
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) treatment with a 530- to 750-nm filter
Study: 10217341
Drug: Oral sustained
Normalized name: Sustain Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained release morphine (MST)
Study: 10217341
Drug: Rectal morphine
Normalized name: morphine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal morphine sulfate suppositories (MSR)
Study: 1346956
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily gentamicin (4 mg/kg/day)
Study: 1346956
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily gentamicin (4 mg/kg/day)
Study: 1346956
Drug: Both dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosage schedules of gentamicin
Study: 6465510
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg promethazine i.m. 45 min before histamine infusion + 400 mg cimetidine i.m. 120 min before histamine infusion
Study: 6465510
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg promethazine i.m. 45 min before histamine infusion
Study: 27672108
Drug: Copanlisib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib at a maximum tolerated dose (MTD) of 0.8 mg/kg, administered as three weekly intravenous infusions per 28-day cycle.
Study: 25427070
Drug: Intralesional bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional bleomycin (1 mg/ml) after paring the hyperkeratotic tissue
Study: 18945992
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (20 microg/kg per day)
Study: 12634581
Drug: Lopinavir/ritonavir 300/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir 300/75 mg/m2 twice daily (after initial dosing of 230/57.5 mg/m2 or 300/75 mg/m2)
Study: 12634581
Drug: Lopinavir/ritonavir 300/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir 300/75 mg/m2 twice daily